SCHEDULE: Vanguard Discloses Stake in Anika Therapeutics

Vanguard Capital Management has reported a 4.95% ownership stake in Anika Therapeutics Inc. as of June 30, 2026.

Summary

• Vanguard Capital Management, through its affiliates and managed accounts, has acquired a beneficial ownership of 659,216 shares of Anika Therapeutics Inc. common stock.
• This holding represents 4.95% of the class of securities.
• The filing indicates that Vanguard has sole dispositive power over these shares and shared voting power with no other entity.
• The reporting is an amendment to a previous filing, dated June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of an institutional investor's stake and does not provide new operational or financial information about the company itself.

Positives

• Vanguard Capital Management, a significant institutional investor, has taken a notable stake in Anika Therapeutics, potentially signaling confidence in the company's prospects.
• The ownership level of 4.95% is just below the threshold that would typically trigger more stringent disclosure requirements, suggesting a passive investment approach for now.

Negatives

• The filing does not contain any negative financial or operational information about Anika Therapeutics; it solely reports Vanguard's ownership.

Risks

• The filing does not explicitly mention any risks related to Anika Therapeutics. The primary risk for Vanguard would be the potential decline in the stock price of Anika Therapeutics.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding Anika Therapeutics' future performance.

Management Comments

• In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd.
• This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power.
• This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.
• Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.
• No one other person's interest in the securities reported herein is more than 5%.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by large asset managers like Vanguard often indicate a passive investment strategy, focusing on portfolio diversification rather than active control. This filing suggests Anika Therapeutics is a component within Vanguard's broader investment universe.

Stakeholder Impact

• Shareholders: The filing indicates increased institutional interest, which can be perceived positively, but the passive nature of the stake suggests no immediate change in control or strategy.
• Management of Anika Therapeutics: May see this as validation of their strategy, but no direct impact on operations is indicated.
• Potential Investors: The filing provides transparency on a significant shareholder, which can be a factor in investment decisions.

Next Steps

• Vanguard Capital Management will continue to monitor its investment in Anika Therapeutics.
• Anika Therapeutics will continue its business operations as usual, subject to market conditions and its strategic plans.

Key Dates

Keywords

Anika Therapeutics, Vanguard Capital Management, Schedule 13G, Ownership Stake, Common Stock, Institutional Investor, SEC Filing, Malvern, PA